NCT03459222
Recruiting
March 8, 2018
May 6, 2022
Brief summary:
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.
N/A
Arm | Intervention/treatment |
---|---|
Experimental: Arm A Relatlimab + Nivolumab + BMS-986205 |
Biological: Relatlimab Specified dose on specified days Biological: Nivolumab Specified dose on specified days Drug: BMS-986205 Specified dose on specified days |
Experimental: Arm B Relatlimab + Nivolumab + Ipilimumab |
Biological: Relatlimab Specified dose on specified days Biological: Nivolumab Specified dose on specified days Biological: Ipilimumab Specified dose on specified days |
Inclusion Criteria: Histologic or cytologic confirmation of select incurable solid malignancies that are advanced (metastatic and/or unresectable), with measurable disease per RECIST v1.1 Available tumor tissue for biomarker analysis Eastern Cooperative Oncology Group Performance Status (ECOG) status of 0 or 1 Exclusion Criteria: Known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease History of interstitial lung disease / pneumonitis Prior malignancy active within the previous 2 years except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent Other protocol-defined inclusion/exclusion criteria apply
Contact: BMS Study Connect Contact Center www.BMSStudyConnect.com 855-907-3286 Clinical.Trials@bms.com
Contact: First line of the email MUST contain NCT # and Site #.
United States, California
Local Institution - 0006
Duarte
United States, Colorado
University Of Colorado
Aurora
United States, Maryland
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore
United States, Missouri
Washington University School OF Medicine-Siteman Cancer Center
Saint Louis
United States, Ohio
Local Institution
Cleveland
United States, Tennessee
The West Clinic, P.C.
Germantown
United States, Washington
Local Institution
Seattle
Australia, New South Wales
Local Institution - 0012
Wollstonecraft
Australia, Western Australia
Linear Clinical Research Ltd
Nedlands
France
Local Institution - 0017
Marseille Cedex 5
France
Institut Claudius Regaud
Toulouse
France
Local Institution - 0015
Villejuif
Italy
Local Institution - 0010
Forlì
Italy
Istituto Nazionale Tumori Fondazione Pascale
Napoli
Italy
Local Institution
Roma
Spain
Hospital Clinic I Provincial
Barcelona
Spain
Local Institution
Madrid
Spain
Centro Integral Oncologico Clara Campal
Madrid
Spain
Local Institution - 0022
Málaga
Spain
Clinica Universidad de Navarra
Pamplona
Switzerland
Chu Vaudois Lausanne
Lausanne
Switzerland
Local Institution - 0007
Zuerich
United Kingdom
Local Institution - 0014
Newcastle Upon Tyne
United Kingdom
Local Institution
Oxford
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb